Phase III trial for once-monthly aripiprazole halted early on positive results
This article was originally published in Scrip
Executive Summary
The independent data monitoring committee for a US Phase III trial with a new once-monthly formulation of Otsuka Pharmaceutical's antipsychotic, Abilify (aripiprazole), has recommended that the study be terminated early, following a positive interim analysis.